

DAFTAR PUSTAKA

1. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. *CA Cancer J Clin.* 2022;72(6):524–41.
2. Burstein HJ. Systemic Therapy for Estrogen Receptor–Positive, HER2–Negative Breast Cancer. *New England Journal of Medicine.* 2020;383(26):2557–70.
3. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *New England Journal of Medicine.* 2017;377(19):1836–46.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144(5):646–74.
5. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. *Clinical Cancer Research.* 2018;24(12):2804–11.
6. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. *Breast Cancer Res Treat.* 2018;167(3):671–86.
7. Beatty GL, Gladney WL. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. *Clinical Cancer Research.* 2015;21(4):687–92.
8. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell.* 2017;168(4):707–23.
9. Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma dedifferentiation in resistance to PD-1 inhibition. *Nat Commun.* 2020;11(1):1897.
10. Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. *Hum Immunol.* 1996;50(2):127–34.
11. Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. *Proc Natl Acad Sci U S A.* 2010;107(31):13794–9.
12. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc Natl Acad Sci U S A.* 2016;113(21):5999–6004.
13. Wang Q, Ding H, He Y, Li X, Cheng Y, Xu Q, et al. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/ β -catenin signalling pathway in clear cell renal cell carcinoma. *Cancer Lett.* 2019;444:9–19.
14. Li Y, Zhang M, Zheng X. High Expression of NLRC5 Is Associated with Prognosis of Gastric Cancer. *Open Med.* 2018;13:443–9.
15. Li X, Guo F, Liu Y, Chen HJ, Wen F, Zou B, et al. NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. *Oncol Lett.* 2015;10(3):1533–40.
16. Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S, et al. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. *Sci Transl Med.* 2020;12(551):eaaz5683.

17. Yoshihama S, Cho SX, Yeung J, Pan X, Lizee G, Konganti K, et al. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. *Sci Rep.* 2021;11(1):3258.
18. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
19. World Health Organization. Global Cancer Observatory: Indonesia Population Fact Sheet. 2018. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>.
20. Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *Pan Afr Med J.* 2018;31:163.
21. Perou CM, Sørli T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature.* 2000;406(6797):747–52.
22. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, et al. How basal are triple-negative breast cancers? *Int J Cancer.* 2008;123(1):236–40.
23. McAndrew NP, Finn RS. Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer. *JCO Oncol Pract.* 2021;18(5):319–27.
24. Lammers SWM, Meegdes M, Vriens IJH, Voogd AC, de Munck L, van Nijnatten TJA, et al. Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study. *ESMO Open.* 2024;9(5).
25. Dunn GP, Old LJ, Schreiber RD. The Immunobiology of Cancer Immunosurveillance and Immunoediting. *Immunity.* 2004;21(2):137–48.
26. Palucka AK, Coussens LM. The Basis of Oncoimmunology. *Cell.* 2016;164(6):1233–47.
27. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. *Front Immunol.* 2021;12:636568.
28. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev.* 2018;32(19–20):1267–84.
29. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol.* 2013;13(4):227–42.
30. de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? *Eur J Cancer.* 2016;68:134–47.
31. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. *J Cell Physiol.* 2003;195(3):346–55.
32. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? *Am Soc Clin Oncol Educ Book.* 2019;39:147–64.
33. Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. NLRC5/CITA: A Key Player in Cancer Immune Surveillance. *Trends Cancer.* 2017;3(1):28–38.
34. Benko S, Magalhaes JG, Philpott DJ, Girardin SE. NLRC5 Limits the Activation of Inflammatory Pathways. *The Journal of Immunology.* 2010;185(3):1681–91.

35. Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hösel M, et al. A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. *J Biol Chem*. 2010;285(34):26223–32.
36. Meissner TB, Li A, Liu YJ, Gagnon E, Kobayashi KS. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity. *Biochem Biophys Res Commun*. 2012;418(4):786–91.
37. Yao Y, Wang Y, Chen F, Huang Y, Zhu S, Leng Q, et al. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. *Cell Res*. 2012;22(5):836–47.
38. Biswas A, Meissner TB, Kawai T, Kobayashi KS. Cutting edge: impaired MHC class I expression in mice deficient for *Nlrc5*/class I transactivator. *J Immunol*. 2012;189(2):516–20.
39. Robbins GR, Truax AD, Davis BK, Zhang L, Brickey WJ, Ting JPY. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. *J Biol Chem*. 2012;287(29):24294–303.
40. Cui J, Zhu L, Xia X, Wang HY, Legras X, Hong J, et al. NLRC5 Negatively regulates the NF- κ B and type I interferon signaling pathways. *Cell*. 2010;141(3):483–96.
41. Rodriguez GM, Bobbala D, Serrano D, Mayhue M, Champagne A, Saucier C, et al. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8⁺ T lymphocytes. *Oncoimmunology*. 2016;5(6):1–12.
42. Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, et al. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. *Sci Transl Med*. 2020;12(565).
43. Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. *J Immunother Cancer*. 2020;8(2).
44. Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. *Oncoimmunology*. 2018;7(10):e1490854.
45. Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Györffy B, et al. Classical pathology and mutational load of breast cancer - integration of two worlds. *J Pathol Clin Res*. 2015;1(4):225–38.
46. Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Hurlings HM, et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. *Oncoimmunology*. 2018;7(12):e1509820.
47. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. *JAMA Oncol*. 2016;2(10):1354–60.
48. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol*. 2018;19(1):40–50.
49. Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, et al. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of

- Randomized Trials in Adjuvant and Neoadjuvant Setting. *Oncologist*. 2016;21(3):283–91.
50. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. *Journal of Clinical Oncology*. 2013;31(7):860–7.
 51. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. *Oncoimmunology*. 2012;1(7):1104–10.
 52. Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. *Oncoimmunology*. 2017;6(5):e1305531.
 53. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. *Nat Commun*. 2017;8(1):1136.
 54. de Kruijf EM, van Nes JGH, Sajet A, Tummers QRJG, Putter H, Osanto S, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. *Clin Cancer Res*. 2010;16(4):1272–80.
 55. Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, et al. Clinical implication of HLA class I expression in breast cancer. *BMC Cancer*. 2011;11:454.
 56. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *Int J Cancer*. 2005;117(2):248–55.
 57. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. *Nat Med*. 2015;21(10):1128–38.
 58. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*. 2018;379(22):2108–21.
 59. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*. 2020;396(10265):1817–28.
 60. Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. *Cancer Immunol Immunother*. 2021;70(3):607–17.
 61. Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. *Cancer*. 2018;124(10):2086–103.
 62. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. *Nat Commun*. 2017;8(1):15081.
 63. Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. *Nat Rev Genet*. 2012;13(7):484–92.
 64. Rhee I, Bachman KE, Park BH, Jair KW, Yen RWC, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature*. 2002;416(6880):552–6.

65. Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. *Signal Transduct Target Ther.* 2019;4(1):62.
66. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. *Nat Genet.* 2003;33(3S):245–54.
67. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med.* 2003;349(21):2042–54.
68. Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. *Clin Epigenetics.* 2018;10(1):78.
69. Dewi DL, Mohapatra SR, Blanco Cabanes S, Adam I, Somarribas Patterson LF, Berdel B, et al. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. *Oncoimmunology.* 2017;6(2):1–12.
70. Micevic G, Thakral D, McGeary M, Bosenberg MW. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival. *Pigment Cell Melanoma Res.* 2019;32(3):435–40.
71. Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. *Nat Commun.* 2018;9(1):248.
72. Luker AJ, Graham LJ, Smith TMJ, Camarena C, Zellner MP, Gilmer JJS, et al. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer. *BMC Immunol.* 2020;21(1):8.
73. Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. *Tumour Biol.* 2014;35(6):5753–62.
74. Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, et al. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. *Cancer Immunol Immunother.* 2016;65(9):1061–73.
75. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. *Nature.* 2012;490(7418):61–70.
76. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2(5):401–4.
77. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013;6(269):p11.
78. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell.* 2015;163(2):506–19.
79. Díez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. *Epigenetics Chromatin.* 2015;8(1):22.
80. Györfly B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer

- prognosis using microarray data of 1,809 patients. *Breast Cancer Res Treat.* 2010;123(3):725–31.
81. Brueffer C, Vallon-Christersson J, Grabau† D, Ehinger A, Häkkinen J, Hegardt C, et al. Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. *JCO Precis Oncol.* 2018;(2):1–18.
 82. Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. NLRC5/CITA: A Key Player in Cancer Immune Surveillance. *Trends Cancer.* 2017;3(1):28–38.
 83. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc Natl Acad Sci U S A.* 2016;113(21):5999–6004.
 84. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. *Cell.* 2021;184(3):596-614.e14.
 85. Gorbachev A V, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. CXC Chemokine Ligand 9/Monokine Induced by IFN- γ Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors. *The Journal of Immunology.* 2007;178(4):2278–86.
 86. Karin N. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. *Front Immunol.* 2020;11:976.
 87. Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022;12(1):31–46.
 88. Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. *Oncoimmunology.* 2017;6(5):1–14.
 89. Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN- γ in tumor progression and regression: a review. *Biomark Res.* 2020;8(1):49.
 90. Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang RF. Enhanced TLR-induced NF- κ B signaling and type I interferon responses in NLRC5 deficient mice. *Cell Res.* 2012;22(5):822–35.
 91. Yoshihama S, Cho SX, Yeung J, Pan X, Lizee G, Konganti K, et al. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. *Sci Rep.* 2021;11(1):3258.
 92. Lv L, Wei Q, Wang Z, Zhao Y, Chen N, Yi Q. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. *Front Bioeng Biotechnol.* 2021;9:690186.
 93. Zaghlool SB, Kühnel B, Elhadad MA, Kader S, Halama A, Thareja G, et al. Epigenetics meets proteomics in an epigenome-wide association study with circulating blood plasma protein traits. *Nat Commun.* 2020;11(1):15.
 94. Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. *Breast Cancer Research.* 2019;21(1):142.
 95. Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S, et al. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. *Sci Transl Med.* 2020;12(551):eaaz5683.